Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Velling, S. Pabst, D. Skowasch, C. Grohé (Bonn, Berlin, Germany). Effects of omalizumab in asthmatic patients with neurodermatitis. Eur Respir J 2008; 32: Suppl. 52, 2010

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 663s Year: 2006 Efficacy of omalizumab in patients with concomitant allergic asthma and atopic dermatitis: a pilot study Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Effect of adding montelukast on asthma and rhinitis in asthma patients with concomitant allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 121s Year: 2006 Diagnosis and treatment of allergic rhinitis in asthmatic children Source: Annual Congress 2009 - Allergic rhinitis and its impact on asthma in children Year: 2009 Safety of omalizumab therapy in children with allergic asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 The effectiveness of omalizumab in steroid-dependent asthma patients Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Efficacy of symbicort administration in patients with bronchial asthma Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Follow-up of patients with moderate-severe allergic asthma treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Systemic steroid use in children with allergic (IgE-mediated) asthma receiving omalizumab Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Effect of desloratadine on patients suffer from allergic rhinitis and bronchial hyperreactivity Source: Eur Respir J 2003; 22: Suppl. 45, 135s Year: 2003 Treatment and outcomes in patients with asthma and allergic rhinitis Source: Eur Respir J 2005; 26: Suppl. 49, 576s Year: 2005 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Omalizumab in severe adult atopic dermatitis associated to mild asthma treated with omalizumab Source: Annual Congress 2012 - Asthma: assessment and treatment Year: 2012 Effects of anti-IgE on asthma exacerbations Source: Eur Respir J 2003; 22: Suppl. 45, 12s Year: 2003 Efficacy of ruzam in the treatment of patients with perennial allergic rhinitis Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 Safety and efficacy of omalizumab in children with allergic asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011